← Oncology Approval Tracker

FDA DECISION ·

Epkinly

epcoritamab-bysp · Genmab US

Accelerated approvalNew therapyLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma after at least two systemic lines.

LAMPGEN ANALYSIS

Why it matters

The accelerated approval added a subcutaneous CD20-directed bispecific for later-line large B-cell lymphoma.

What research teams should watch

Verify histology and treatment history, and arrange step-up dosing and post-dose observation.

PRIMARY RECORDS

Sources